Global case tally for COVID-19 nears 124 million as U.S. health experts question AstraZeneca trial data


The company may have included “outdated information” in U.S. trial results for its COVID-19 vaccine, providing an “incomplete view of the efficacy data,” a U.S. federal health agency said in a highly unusual statement released after midnight.



said Monday that interim data from a major late-stage trial found the vaccine was 79% effective in preventing symptomatic COVID-19 and 100% effective at preventing people from falling seriously ill. The vaccine also proved safe, a key issue coming after some European countries temporarily halted its use last week after a small number of people reported blood clotting issues after getting a jab.

But the National Institute of Allergy and Infectious Diseases (NIAID) said it had been notified by the Data and Safety Monitoring Board (DSMB), an independent committee overseeing the U.S. trial, that it was “concerned by information released by AstraZeneca on initial data from its COVID-19 vaccine clinical trial.”

“The DSMB expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data,” the NIAID said. “We urge the company to work with the DSMB to review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible.

AstraZeneca said in a statement that the numbers it published on Monday were based on a pre-specified interim analysis with a data cut-off of Feb. 17.

Read also: CDC changes school guidance, allowing K-12 students to sit 3 feet apart if wearing masks

“We have reviewed the preliminary assessment of the primary analysis and the results were consistent with the interim analysis. We are now completing the validation of the statistical analysis,” the company said. It added that it will “immediately” engage with the DSMB to share its primary analysis with the most up to date efficacy data. The company intends to issue results of the primary analysis within 48 hours.

The news casts a cloud on AstraZeneca’s other aim, which is to submit the vaccine for emergency use authorization in the U.S., where it would offer a fourth alternative, joining the vaccines developed by Pfizer Inc.

and German partner BioNTech SE
Moderna Inc.

and most recently Johnson & Johnson

Dr. Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases, told ABC News that the AstraZeneca shot is “likely very good,” but that the data presented was questioned by independent medical experts at the National Institutes for Health.

He said the U.S. Food and Drug Administration will review the data when it submits its application for an EUA and “will independently go over every bit of data themselves.”

Others suggested the problem may lie with the company’s inexperience in dealing with U.S. regulators.

The U.S. is pushing to expand its vaccine program and get jabs into arms as quickly as possible, in an effort to avoid mass transmission of new variants of the virus that are creating spikes in cases in other places, notably Europe and Brazil.

German Chancellor Angela Merkel said Tuesday the variant that was first detected in the U.K. has now become the dominant strain in Germany and described it as a “new pandemic.”

“Essentially, we have a new virus… it is much deadlier, much more infectious and infectious for much longer,” she said as she announced a strict lockdown over the Easter holiday period.

In France, President Emmanuel Macron said his country’s vaccination drive will be greatly expanded in April, as it works to combat a third wave of infections. France should be vaccinating “morning, noon and evening,” Macron said on a visit to a vaccine site in the northern town of Valenciennes, as AFP reported. The army will set up 35 mass vaccination centers, he said.

In the U.S. the Centers for Disease Control and Prevention’s vaccine tracker is showing that as of 6 a.m. ET Monday, 156.7 million doses had been distributed to states, 126.5 million doses have been administered and 82.7 million people have had at least one dose, equal to 24.9% of the population. So far, 44.9 million people are fully vaccinated, equal to 13.5% of the population.

The global tally for the coronavirus-borne illness rose above 123.7 million on Tuesday, according to data aggregated by Johns Hopkins University, with the U.S. accounting for 24% of cases at 29.8 million. The global death toll grew to 2.72 million, with the U.S. toll of 542,949 accounting for 20.0%.

More than 70 million people have recovered from COVID-19, the data show.

The U.S. added at least 55,621 new cases on Monday, according to a New York Times tracker, and at least 650 people died. The U.S. has averaged 54,190 cases a day for the last week, down 8% from the average two weeks ago.

Brazil is second globally in cases at 12 million and also second with a death toll at 295,425.

India is third worldwide in cases with 11.7 million and fourth in deaths at 160,166.

Mexico is third by deaths at 198,239 and 13th highest by cases.

The U.K. has 4.3 million cases and 126,411 deaths, the highest in Europe and fifth highest in the world.

China, where the virus was first discovered late last year, has had 101,560 confirmed cases and 4,839 deaths, according to its official numbers.

Source link